Bacteriophage Based-Vaccine System
Summary:
Researchers at NCI seek licensing and/or co-development research collaborations for further development of the Bacteriophage based-vaccine system.
High Efficacy Vaccine and Microbicide Combination For Use Against HIV
Summary:
NCI is seeking research co-development partners and/or licensees to evaluate, further develop or commercialize this high efficacy vaccine and microbicide combination for use against HIV.
Immunogens for Use in a High Efficacy HIV Vaccine
Summary:
The Vaccine Branch is seeking statements of capability or interest from parties interested in licensing V1-deleted immunogens to further develop, evaluate, or commercialize an improved HIV vaccine.
Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection
Summary:
Inventors are seeking licensing and/or co-development research collaborations for a unique novel molecular Adjuvanted Mucosal Subunit Vaccine to prevent SARS-CoV-2 transmission and infection.
Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease
Description of Technology:
The manner by which cancers evade the immune response is not well-understood. What is known is that the manner is an active process that regulates immune responses employing at least two types of suppressive cells, myeloid-derived suppressive cells and regulatory T cells (Tregs), a key subset of CD4+ T cells that controls peripheral tolerance to self- and allo-antigens. Tregs are considered to play a key role in the escape of cancer cells from anti-tumor effector T cells.
Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine
The invention, a stabilized recombinant prefusion F protein (pre F), is a candidate subunit vaccine for Respiratory Syncytial Virus (RSV). Pre-F is stabilized in the prefusion conformation and displays epitopes not present in postfusion F protein. Several potent RSV neutralizing antibodies bind pre F, but not postfusion F. Therefore, immunization with pre F may elicit an immune response superior to the response generated by postfusion F.
Fusion Glycoprotein Vaccine for Human Metapneumovirus
Human metapneumovirus (hMPV), a negative, single-stranded RNA virus, accounts for approximately 5-15% of infant respiratory tract infections and poses a severe risk of disease and hospitalization in both the elderly and the immunocompromised. Investigators at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have generated an hMPV fusion glycoprotein (“F protein”) stabilized in a prefusion conformation.
Broadly neutralizing influenza hemagglutinin stem-directed antibodies
In 2023, the World Health Organization (WHO) reported roughly 3 to 5 million cases of severe influenza worldwide, resulting in approximately 290,000 to 650,000 deaths. Given the high disease burden, the needs for both prophylactic and therapeutic influenza strategies remain significant. However, current treatments for influenza are susceptible to resistance and are useful for only a limited post-infection period.
Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response
Description of Technology:
The development of an effective HIV vaccine has been ongoing. HIV sequence diversity and immunodominance are major obstacles in the design of an effective vaccine. Researchers at the National Cancer Institute (NCI) developed a novel vaccine strategy combining both DNA and mRNA vaccination to induce an effective immune response. This combination strategy could also be used to develop vaccines against cancer or other infectious diseases (ex. SARS-CoV-2).
MenAfriVac, Low-Cost Meningitis Vaccine, Wins LES Deals of Distinction Award
The 2014 Deals of Distinction Award from the LES Industry-University-Government Interface Sector (IUGI) went to the U. S. Food and Drug Administration (FDA), National Institutes of Health (NIH), PATH, and the Serum Institute of India (SII) for MenAfriVac, a low-cost meningitis vaccine designed for use in sub-Saharan Africa.